Petzke Frank, Bock Frietjof, Hüppe Michael, Nothacker Monika, Norda Heike, Radbruch Lukas, Schiltenwolf Marcus, Schuler Matthias, Tölle Thomas, Viniol Anika, Häuser Winfried
Pain Medicine, Department of Anesthesiology, University Medical Center Göttingen, Göttingen, Germany.
Orthopaedics at the Green Tower, Ravensburg, Germany.
Pain Rep. 2020 Aug 20;5(5):e840. doi: 10.1097/PR9.0000000000000840. eCollection 2020 Sep-Oct.
The opioid epidemic in North America challenges national guidelines worldwide to define the importance of opioids for the management of chronic noncancer pain (CNCP).
The second update of the German guidelines on long-term opioid therapy for CNCP was developed by 26 scientific associations and 2 patient self-help organizations. A systematic literature search in CENTRAL, Medline, and Scopus (to May 2019) was performed. Meta-analyses of randomized controlled trials and open-label extension studies with opioids for CNCP were conducted. Levels of evidence were assigned according to the Oxford Centre for Evidence-Based Medicine classification system. The formulation and strength of recommendations were established by multistep formalized procedures to reach a consensus according to German Association of the Medical Scientific Societies regulations. The guidelines underwent external review by 4 experts and public commentary.
Opioids are one drug-based treatment option for short- (4-12 weeks), intermediate- (13-26 weeks), and long-term (>26 weeks) therapy of chronic pain in osteoarthritis, diabetic polyneuropathy, postherpetic neuralgia, and low back pain. Contraindications are primary headaches, functional somatic syndromes, and mental disorders with the (cardinal) symptom of pain. For specified other clinical pain conditions, short- and long-term therapy with opioids should be evaluated on an individual basis. Long-term therapy with opioids is associated with relevant risks.
Responsible application of opioids requires consideration of possible indications and contraindications, as well as regular assessment of clinical response and adverse effects. Neither uncritical opioid prescription nor general rejection of opioids is justified in patients with CNCP.
北美地区的阿片类药物泛滥对全球各国的指南提出了挑战,这些指南旨在界定阿片类药物在慢性非癌性疼痛(CNCP)管理中的重要性。
德国关于CNCP长期阿片类药物治疗的指南第二次更新由26个科学协会和2个患者自助组织制定。对CENTRAL、Medline和Scopus(截至2019年5月)进行了系统的文献检索。对用于CNCP的阿片类药物的随机对照试验和开放标签扩展研究进行了荟萃分析。证据水平根据牛津循证医学中心分类系统进行划分。推荐意见的制定和强度通过多步骤的正式程序确定,以根据德国医学科学协会联合会的规定达成共识。该指南接受了4位专家的外部审查和公众评议。
阿片类药物是用于骨关节炎、糖尿病性多发性神经病变、带状疱疹后神经痛和腰痛等慢性疼痛的短期(4 - 12周)、中期(13 - 至26周)和长期(>26周)治疗的一种基于药物的治疗选择。禁忌证包括原发性头痛、功能性躯体综合征以及以疼痛为(主要)症状的精神障碍。对于特定的其他临床疼痛情况,应根据个体情况评估阿片类药物的短期和长期治疗。阿片类药物的长期治疗存在相关风险。
阿片类药物的合理应用需要考虑可能的适应证和禁忌证,以及定期评估临床反应和不良反应。对于CNCP患者,不加批判地开具阿片类药物处方或一概拒绝使用阿片类药物都是不合理的。